These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
469 related articles for article (PubMed ID: 17626366)
1. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro. Strobl JS; Cassell M; Mitchell SM; Reilly CM; Lindsay DS J Parasitol; 2007 Jun; 93(3):694-700. PubMed ID: 17626366 [TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
3. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. Codd R; Braich N; Liu J; Soe CZ; Pakchung AA Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319 [TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages. Han SB; Lee JK Arch Pharm Res; 2009 Apr; 32(4):613-24. PubMed ID: 19407980 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001 [TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor uses p21(Cip1) to maintain anergy in CD4+ T cells. Dagtas AS; Edens RE; Gilbert KM Int Immunopharmacol; 2009 Oct; 9(11):1289-97. PubMed ID: 19664724 [TBL] [Abstract][Full Text] [Related]
10. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Romanski A; Bacic B; Bug G; Pfeifer H; Gul H; Remiszewski S; Hoelzer D; Atadja P; Ruthardt M; Ottmann OG Haematologica; 2004 Apr; 89(4):419-26. PubMed ID: 15075075 [TBL] [Abstract][Full Text] [Related]
11. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. Gu W; Nusinzon I; Smith RD; Horvath CM; Silverman RB Bioorg Med Chem; 2006 May; 14(10):3320-9. PubMed ID: 16434199 [TBL] [Abstract][Full Text] [Related]
12. Schistosoma mansoni: developmental arrest of miracidia treated with histone deacetylase inhibitors. Azzi A; Cosseau C; Grunau C Exp Parasitol; 2009 Mar; 121(3):288-91. PubMed ID: 19094990 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel isoform-selective inhibitors within class I histone deacetylases. Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486 [TBL] [Abstract][Full Text] [Related]
14. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Sekhavat A; Sun JM; Davie JR Biochem Cell Biol; 2007 Dec; 85(6):751-8. PubMed ID: 18059533 [TBL] [Abstract][Full Text] [Related]
15. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744 [TBL] [Abstract][Full Text] [Related]
18. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC Clin Cancer Res; 2001 Apr; 7(4):971-6. PubMed ID: 11309348 [TBL] [Abstract][Full Text] [Related]
19. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934 [TBL] [Abstract][Full Text] [Related]
20. Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils. Ishihara K; Hong J; Zee O; Ohuchi K Br J Pharmacol; 2004 Jul; 142(6):1020-30. PubMed ID: 15210580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]